Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 4/20 | 0.33 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17997141 | 0.86 | SMYD2 (0.36) | SMYD2MAPTCYP3A4HTTSMN1; SMN2 | |
| SCHEMBL14576007 | 0.84 | BTN3A1 (0.33) | BTN3A1SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL14616409 | 0.84 | BTN3A1 (0.33) | BTN3A1SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL1443819 | 0.84 | BTN3A1 (0.33) | BTN3A1SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL16615644 | 0.83 | SMYD2 (0.35) | SMYD2MAPTCYP3A4HTTSMN1; SMN2 | |
| SCHEMBL1443774 | 0.83 | BTN3A1 (0.32) | BTN3A1SMYD2MAPT | |
| SCHEMBL14576030 | 0.83 | BTN3A1 (0.32) | BTN3A1SMYD2MAPT | |
| SCHEMBL1443622 | 0.80 | BTN3A1 (0.39) | BTN3A1SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL3092378 | 0.80 | MAPT (0.41) | MAPTCYP3A4 | |
| SCHEMBL11890219 | 0.80 | MAPT (0.41) | MAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240261426-A1 | CONJUGATES COMPRISING PHOSPHOANTIGENS AND THEIR USE IN THERAPY | BYONDIS B.V. (NL) | 2024-08-08 | — | — | US | disclosed |
| EP-4362982-A1 | CONJUGATES COMPRISING PHOSPHOANTIGENS AND THEIR USE IN THERAPY | Byondis B.V. (NL) | 2024-05-08 | — | — | EP | disclosed |
| CN-117794581-A | Conjugates comprising phosphoantigen and their use in therapy | 拜奥迪斯私人有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2023275025-A1 | CONJUGATES COMPRISING PHOSPHOANTIGENS AND THEIR USE IN THERAPY | BYONDIS B.V. (NL) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261426-A1 | CONJUGATES COMPRISING PHOSPHOANTIGENS AND THEIR USE IN THERAPY | CD47, PTMS, PAG1 | BTN3A1 458/4885SMYD2 2946/4885MAPT 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.